Baseline clinical characteristics by body mass index(BMI) category and treatment group
| Variable | Patient status# | Montelukast | Beclomethasone | Placebo |
| BMI kg·m−2 | Normal | 21.98 (16–25) | 21.99 (15–25) | 22.08 (16–25) |
| Overweight | 27.05 (25–30) | 27.21 (25–30) | 27.14 (25–30) | |
| Obese | 33.78 (30–51) | 34.40 (30–65) | 33.21 (30–48) | |
| FEV1 L | Normal | 2.41±0.65 | 2.35±0.63 | 2.49±0.68 |
| Overweight | 2.35±0.67 | 2.23±0.65 | 2.27±0.68 | |
| Obese | 2.13±0.66 | 2.24±0.72 | 2.22±0.68 | |
| FEV1 %¶ | Normal | 68.04±10.66 | 67.17±10.97 | 68.55±10.89 |
| Overweight | 67.00±10.58 | 66.31±11.57 | 65.67±11.49 | |
| Obese | 64.77±11.75 | 66.60±10.56 | 66.88 ±11.35 | |
| Reversibility % | Normal | 28.03±13.26 | 27.67±13.38 | 26.76±11.47 |
| Overweight | 28.61±13.09 | 27.74±13.42 | 28.92±13.45 | |
| Obese | 29.32±15.04 | 25.54±10.33 | 25.97±13.17 |
Data are presented as mean (range) or mean±sd. FEV1: forced expiratory volume in one second; % pred: percentage predicted. #: Normal: BMI <25.0 kg·m−2; overweight: 25–29.9 kg·m−2; obese: BMI ≥30.0 kg·m−2. ¶: predicted mean±sd.